Aarti Drugs Ltd, part of the Aarti Group of Industries, engaged in manufacturing APIs, pharma intermediates, specialty chemicals, and formulations, reported strong results for Q2FY26.
Financial Highlights:
- Revenues increased 9.2% year-on-year to ₹653 crore from ₹598 crore.
- Total expenses rose 7.04% to ₹593 crore from ₹554 crore.
- Consolidated net profit climbed 28.57% to ₹45 crore from ₹35 crore.
- Earnings per share improved 29.40% to ₹4.93 from ₹3.81.
Profit growth was fuelled by higher sales volumes, improved operational efficiencies, and effective cost management.
Outlook:
Aarti Drugs is focused on expanding its product portfolio, strengthening exports, and investing in capacity enhancements and process improvements to sustain long-term growth.
Explore the company’s past earnings and latest concall transcripts, click here to visit the AlphaStreet India News Channel.
Most Popular
Cochin Shipyard Ltd (COCHINSHIP) Q4 FY22 Earnings Concall Transcript
Cochin Shipyard Limited (NSE:COCHINSHIP) Q4 FY22 Earnings Concall dated May. 26, 2022 Corporate Participants: Madhu S Nair -- Chairman & Managing Director Jose V J -- Director Finance Analysts: Vastupal Shah
All you need to know about Antony Waste Handling Cell in one article
Can you guess the name of the company that was listed during the IPO frenzy in 2020 and is the second largest player in the Indian municipal waste management industry?
Demystifying the Leading Non-Ferrous Recycling Company of India
“Hey, how is the market doing today?” “Oh!, its falling tremendously since morning” I am sure news like these might be a common topic of discussion for you nowadays. Interestingly,